Business Monitor International


Netherlands Pharmaceuticals & Healthcare Report

Published 13 February 2014

  • 120 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Netherlands Pharmaceuticals & Healthcare Report

BMI View: We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act, which will subdue the outlook for both patented and generic drugmakers in the country. This comes d espite expectations for a return to positive economic growth in 2014, as the Dutch government will persist with austerity measures to comply with EU budgetary requirements. While our short-term outlook for healthcare expenditure is steady, spending growth has levelled off since 2011, with the proportion of GDP allocated to healthcare projected to gradually shrink over our forecast period to 2023 .

Headline Expenditure Projections

  • Pharmaceuticals: EUR6.87bn (US$9.07bn) in 2013 to EUR6.74bn (US$8.56bn) in 2014; -1.9% in local currency terms and -5.6% in US dollar terms.

  • Healthcare: EUR76.07bn (US$100.41bn) in 2013 to EUR77.56bn (US$98.50bn) in 2013; 2.0% in local currency terms and -1.9% in US dollar terms.

Risk/Reward Ratings

The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Ratings (RRRs) for the 14 key Western European markets, and remains 10 th in our ratings for Q214. The country fell from eighth in Q413. At an unchanged 66, its overall RRR score remains only slightly below the regional average of 67. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

  • In December 2013, the European Commission (EC) imposed fines of EUR10.80bn (US$14.62bn) and EUR5.49bn (US$7.44bn) on the Dutch subsidiaries of Johnson & Johnson and Novartis respectively. According to the EC, in July 2005 the subsidiaries concluded an anticompetitive agreement to delay the market entry of cheaper...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Netherlands Pharmaceutical Sales, Historical Data And Forecasts
16
Healthcare Market Forecast
17
Table: Netherlands Healthcare Expenditure Trends, Historical Data and Forecasts
19
Table: Netherlands Government Healthcare Expenditure Trends, Historical Data and Forecasts
20
Table: Netherlands Private Healthcare Expenditure Trends, Historical Data and Forecasts
20
Prescription Drug Market Forecast
21
Table: Netherlands Prescription Drug Market Indicators, Historical Data and Forecasts
23
Patented Drug Market Forecast
24
Table: Netherlands Patented Drug Market Indicators, Historical Data and Forecasts
25
Generic Drug Market Forecast
25
Table: Netherlands Generics Drug Market Indicators, Historical Data And Forecasts
27
OTC Medicine Market Forecast
27
Table: OTC Medicine Sales Indicators By Category, 2008-2010
29
Table: Netherlands Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
30
Pharmaceutical Trade Forecast
31
Table: Netherlands Pharmaceutical Trade Data And Forecasts (US$mn)
32
Table: Netherlands Pharmaceutical Trade Data And Forecasts (EURmn)
32
Other Healthcare Data
33
Table: Number Of Physicians By Type, 2007-2010
34
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Table: Netherlands - Economic Activity
41
Industry Risk Reward Ratings
42
Western Europe Risk/Reward Ratings
42
Netherlands Risk/Reward Ratings
46
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Healthcare Sector
51
Healthcare Funding
53
Health Insurance
54
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
55
Healthcare Insurance Developments
59
Table: Biosimilars Approved In The EU
60
Research And Development
60
Clinical Trials
63
Biotechnology
66
Regulatory Development
67
Regulatory Developments
68
Intellectual Property Regime
70
Pricing Regime
71
Reimbursement Regime
73
Competitive Landscape
76
Pharmaceutical Industry
76
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
76
Recent Company Activity
78
Pharmaceutical Wholesale Sector
80
Pharmaceutical Retail Sector
81
Company Profile
84
DSM
84
Qiagen
88
Pharming Group
91
Merck & Co
96
Pfizer
99
GlaxoSmithKline
102
Sanofi
104
Novartis
106
Demographic Forecast
109
Demographic Outlook
109
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)
110
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)
111
Table: The Netherlands' Key Population Ratios, 1990-2020
112
Table: The Netherlands' Rural And Urban Population, 1990-2020
112
Glossary
113
Methodology
115
Pharmaceutical Expenditure Forecast Model
115
Healthcare Expenditure Forecast Model
115
Notes On Methodology
116
Risk/Reward Ratings Methodology
117
Ratings Overview
118
Table: Pharmaceutical Risk/Reward Ratings Indicators
118
Indicator Weightings
119

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Netherlands to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc